Terapi Kanker Payudara Stadium Lanjut HER2 (+)
DOI:
https://doi.org/10.55175/cdk.v50i10.915Kata Kunci:
HER2, kanker payudara, stadium lanjutAbstrak
Pada sekitar 15%-20% kanker payudara dijumpai over-ekspresi dan/atau amplifikasi human epidermal growth factor receptor 2 (HER2). Subtipe kanker payudara ini dikaitkan dengan perilaku agresif, kekambuhan tinggi, dan prognosis buruk. Namun, dengan dikenalkannya terapi target HER2, trastuzumab, harapan hidup pasien meningkat. Pada pasien HER2 positif dengan stadium lanjut, taxane yang dikombinasi dengan trastuzumab dan pertuzumab diberikan dalam setting lini pertama. Pada lini kedua dan berikutnya, tersedia beberapa terapi anti-HER2, seperti trastuzumab deruxtecan, tucatinib, T-DM1, neratinib, lapatinib, pyrotinib, margetuximab.
Unduhan
Referensi
Martinez-Saez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17:594-604.
Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020;70:355-74.
Bartelemy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE. Pertuzumab: Development beyond breast cancer. Anticancer Res. 2014;34:1483-92.
Landaverde D, Verma S. Recent treatment advances in HER2-positive metastatic breast cancer: A clinical approach. Clin Pract. 2012;9(3):287-99.
Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open 2022 doi: 10.1016/j.esmoop.2021.100343.
Swain SM, Baselga J, Kim SB, Ro JS, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-34.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-30.
Martinez MT, Perez-Fidalgo JA, Martin-Martorell P, Cejalvo JM, Pons V, Bermejo B, et al. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Crit Rev Oncol/Hematol. 2016;97:96-106.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-91.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743-54.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.
Li LX, Zhang D, Liu BL, Lv D, Zhai JT, Guan XW, et al. Antibody-drug conjugates in HER2-positive breast cancer. Chinese Medical Journal 2022;135(3):261-7.
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on trastuzumab deruxtecan (DS-8201, T-DXd) for HER2 mutation positive non-small cell lung cancer. Lung Cancer: Targets and Therapy 2021;12:103-14.
Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Ann Pharmacother. 2021 doi: 10.1177/1060028021998320.
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;402:105-17.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
Trastuzumab deruxtecan. Product Information [FDA]. 2022 [cited 2022 May 29]. Available from: www.fda.gov.
Jacobson A. Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases. The Oncologist 2022;27(Suppl 1):S3-4.
Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. Cancer Discov. 2022;12:1-9.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
Shah M, Wedam S, Cheng J, Fiero MH, Xia HM, Li F, et al. FDA approval summary: Tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:1220-6.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 2020;38:3138-49.
Xu BH, Yan M, Hu XC, Feng JF, Ouyang QC, Tong ZS, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicenter, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:351-60.
Blair HA. Pyrotinib: First global approval. Drugs 2018 doi: 10.1007/s40265-018-0997-0.
Schlam I, Nunes R, Lynce F. Profile of margetuximab: Evidence to date in the targeted treatment of metastatic HER2-positive breast cancer. Onco Targets and Therapy 2022;15:471-8.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2022 doi: 10.1200/JCO.21.02937.
NCCN clinical practice guidelines in oncology. Breast cancer. Version 4.2023 [cited 2023 May 26]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:2612-35.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
